[{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Charles River Laboratories, Inc \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ Algernon Pharmaceuticals"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Dalton Pharma Services","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dalton Pharma Services \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Dalton Pharma Services \/ Algernon Pharmaceuticals"},{"orgOrder":0,"company":"Hammersmith Medicines Research","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Hammersmith Medicines Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Hammersmith Medicines Research \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hammersmith Medicines Research \/ Algernon Pharmaceuticals"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Akome Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Akome Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Akome Biotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Akome Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IntelGenx \/ atai","highestDevelopmentStatusID":"4","companyTruncated":"IntelGenx \/ atai"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Enveric Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Enveric Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Not Applicable"},{"orgOrder":0,"company":"Blumentech S.L.","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Blumentech S.L.","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blumentech S.L. \/ Terran Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Blumentech S.L. \/ Terran Biosciences"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT6 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Not Applicable"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Laboratorium Ofichem B.V","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Entheon Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entheon Biomedical \/ Ofichem Laboratorium","highestDevelopmentStatusID":"7","companyTruncated":"Entheon Biomedical \/ Ofichem Laboratorium"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Unlimited Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Unlimited Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Unlimited Sciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Unlimited Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Psilera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5HT-1A","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Psilera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Psilera \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Psilera \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Psilera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Psilera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Psilera \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Psilera \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Not Applicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Yale University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Yale University","highestDevelopmentStatusID":"4","companyTruncated":"Algernon Pharmaceuticals \/ Yale University"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Terran Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Terran Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Terran Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Algernon NeuroScience","sponsor":"Dalmore Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon NeuroScience","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Algernon NeuroScience \/ Dalmore Group","highestDevelopmentStatusID":"6","companyTruncated":"Algernon NeuroScience \/ Dalmore Group"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cybin \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Sairiyo Therapeutics \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Sairiyo Therapeutics \/ PharmaTher"},{"orgOrder":0,"company":"Algernon NeuroScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon NeuroScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon NeuroScience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon NeuroScience \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Cybin"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Not Applicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Dispersible","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Cybin"},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Not Applicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","graph1":"Technology","graph2":"Approved","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ATAI Life Sciences \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Dimethyltryptamine
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
